Estudo randomizado | Eficácia de longo prazo e segurança da denervação renal na presença de medicamentos anti-hipertensivos.

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário: Three-year trial of SPYRAL HTN-ON MED shows blood pressure reductions – MedicalXpress

Conteúdos relacionados:

Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.

M-A: Renal denervation for hypertension is associated with a modest reduction in ambulatory blood pressure control (3.61 mm Hg reduction in ambulatory systolic BP and 1.85 mm Hg reduction in ambulatory diastolic BP).

#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.

Meta-Analysis: Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients with Hypertension

Comentário no Twitter

Renal denervation could provide an adjunctive treatment modality in the management of patients with #hypertension, suggests trial assessing long-term efficacy & safety in the presence of antihypertensive drugs: https://t.co/45ojbyhQp3 pic.twitter.com/eg6CXGDGCE

— The Lancet (@TheLancet) April 6, 2022